Cure My Disease

Don't miss your cure!

 Log in / Sign up

A simple body scan may spot fatty liver disease without needles

NCT ID NCT04873258

Diagnosis Sponsor: Richmond Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This study is testing whether a non-invasive tool, called bioimpedance vector analysis, can predict fatty liver disease (MASLD) in healthy volunteers. Researchers will use machine learning to analyze body composition data from about 2000 adults aged 18 to 80. The goal is to create a screening tool that could be used in clinical trials to identify liver issues without invasive procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bioimpedance vector analysis, a non-invasive test that measures body composition using a weak electrical current
What this could lead to
If successful, this could provide a quick, needle-free way to screen for fatty liver disease in clinical trial volunteers, replacing more invasive tests.
What could go wrong
The tool is still being developed and validated, so it may not prove accurate enough for widespread use. Early results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2019

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult male or female volunteers for other clinical trials taking place at the study unit.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female volunteers aged ≥18 to ≤80 years at the date of signing the informed consent. 2. Willingness and ability to provide written, personally signed, and dated informed consent, in accordance with the latest ICH Good Clinical Practice (GCP) Guidelines and applicable regulations. 3. An understanding, ability and willingness to fully comply with project procedures and restrictions. For PART B only: 1\. With a known history of MASLD as evidenced either of: 1. GP diagnosis on HCF 2. Documented Fibroscan or liver US demonstrating MASLD Exclusion Criteria: 1. Known alcoholic liver disease, history of cirrhosis of any other cause (metabolic, viral hepatitis or other) 2. Any other significant previous liver pathology (liver malignancy, portal hypertension, infiltrative liver disease) 3. Alcohol consumption \>30 units per week 4. An Implanted cardiac devices

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fatty liver are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fatty liver disease metabolic dysfunction-associated steatotic liver disease Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fatty liver Healthy MASLD Masld (metabolic dysfunction-associated steatotic liver disease) Obesity and obesity-related medical conditions

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Richmond Pharmacology Ltd. 1a Newcomen St, London Bridge

    RECRUITING

    London, London, SE1 1YR, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.